Summary
Advanced glycation end products (AGEs) are highly reactive compounds that result from a chemical reaction between reducing sugars and amino acids (also known as a Maillard reaction) and from the oxidation of sugars, lipids, and amino acids. These reactions are endogenous, i.e., they occur naturally in the body. Although the formation of AGEs within the body is a part of normal metabolism, a growing body of evidence[1][2][3] suggests that excessive AGE levels promote oxidative stress and inflammation and may therefore increase the risk of developing type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, cancer, Alzheimer’s disease, and infertility.
AGEs were first recognized as being produced within the body under conditions of increased oxidative stress. However, it is now known that dietary AGEs are important contributors[4] to the body’s total AGE concentration, where they become indistinguishable[5] from AGEs produced within the body. The most widely studied AGE is carboxymethyllysine (CML), while another common marker of AGE formation is methylglyoxal (MG).
Examine Database: Endogenous Advanced Glycation End Products
Intervention | Grade | Effect | Detail |
---|---|---|---|
Benfotiamine | D | ||
Lutein | D | ||
Coenzyme Q10 | D | ||
Nicotinamide Mononucleotide |
Research FeedRead all studies
In this randomized controlled trial, supplementing with lutein improved blood lipids, reduced oxidative stress and blood pressure, and lowered advanced glycation end products in participants with central obesity.
References
Examine Database References
- Benfotiamine - Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJEffect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathyPLoS One.(2012)
- Coenzyme Q10 - Mirhashemi SM, Najafi V, Raygan F, Asemi ZThe effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trialARYA Atheroscler.(2016 Jul)
- Nicotinamide Mononucleotide - Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito KNicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.Sci Rep.(2023-Feb-16)
- Lutein - Zhou J, Wang S, Wang Q, Zhao R, Wang D, Xie H, Du Y, Xu Y, Deng J, Huang Y, Liu Y, Peng X, Hao L, Liu LEffect of lutein supplementation on blood lipids and advanced glycation end products in adults with central obesity: a double-blind randomized controlled trial.Food Funct.(2025 Mar 3)